Copy
Press Release June 18, 2020
 

Wuhan General Group Announces Name Change and Rebranding to M2Bio Sciences

MONTREAL, QC / ACCESSWIRE / June 18, 2020, / WUHAN GENERAL GROUP, INC. (WUHN) ("Wuhan" or the "Company"), a bioceutical company focused on alternative plant-based cannabinoids and psilocybin medical research is pleased to announce a corporate name change and rebranding of the company to M2Bio Sciences, Inc (“M2Bio”). The name change was effective June 17, 2020, with the State of Nevada.
 
In addition to the new corporate name, the Company ticker symbol on OTCMarket will change to ‘MMBS’ with the approval of Finra. The Company will issue a press release in the near future announcing the date at which the Corporate name and new ticker symbol will take effect.
 
Along with the name and symbol change, the Company will reveal a new corporate brand identity including a new logo and website. The Company will provide further updates regarding these changes in the near future.
 
Dr. Anna Morera Leralta, CMO of M2Bio, commented, “Our strategic move marks an important milestone in the Company’s growth. By changing our name, we are branding a strong corporate identity that will exactly personify our company in the eyes of the public and investors. Cannabinoid and psychedelic medicine provide our shareholders with access to a rapidly growing market that is altering the future of healthcare we used to know.”
 
"The new name M2Bio has been chosen to better reflect the company’s strategic focus on applying Marijuana and Mushrooms into the roots of its research and development of plant-based medicine and drug discovery, and to mark a new chapter in the Company’s growth. We are so deeply committed to developing innovative, better and safer medicines that will truly help treat patients," said Jeff Robinson, CEO of M2Bio.  


About Wuhan General Group, Inc. / M2Bio Sciences, Inc
 
Wuhan General Group, Inc. through its wholly-owned subsidiary MJ MedTech is a nutraceutical biotechnology company that researches, develops and commercializes a range of CBD-based products under Dr. AnnaRx™ and Medspresso™ brands. In addition, its new wholly-owned division, M2Bio is researching and developing indications for psilocybin new therapies that will help patients who suffer from addiction, mental illness, Alzheimer's and Parkinson's. Our mission is to advance botanical-based medicine to the forefront by deploying best-practice science and medicine, clinical research and emerging technologies. Wuhan is listed and traded on the Over the Counter Bulletin Board of NASDAQ under the trading symbol “WUHN”.

 
For further information:
 
Publicly traded company (OTC Pink: WUHN)
Website: www.wuhn.org
E-mail: info@wuhn.org
Follow us on Twitter: https://twitter.com/WGG_Company
Follow us on Facebook: http://www.facebook.com/wuhn
 


Forward-Looking Statements

Safe Harbour Statement - In addition to historical information, this press release may contain statements that constitute forward-looking statements within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this press release include the intent, belief, or expectations of the Company and members of its management team with respect to the Company's future business operations and the assumptions upon which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties and that actual results may differ materially from those contemplated by such forward-looking statements. Factors that could cause these differences to include, but are not limited to, failure to complete anticipated sales under negotiations, lack of revenue growth, client discontinuances, failure to realize improvements in performance, efficiency and profitability, and adverse developments with respect to litigation or increased litigation costs, the operation or performance of the Company's business units or the market price of its common stock. Additional factors that could cause actual results to differ materially from those contemplated within this press release can also be found on the Company's website. The Company disclaims any responsibility to update any forward-looking statements.


Source: Wuhan General Group, Inc.
 
 
Twitter Twitter
LinkedIn LinkedIn
Facebook Facebook
 
 

                     Wuhan General Group, Inc.  |  6500 Transcanada Hwy 400   |  Quebec, Canada H9R0A5

 

Copyright © 2020 Wuhan General Group or its affiliates. All rights reserved. Medspresso, the logo, and all other related logos are trademarks of Wuhan General Group Inc or its affiliates.

You've received this email because  you opted in via our website or have shown an interest in the past. If you wish to change how you receive these emails?
You can update your preferences or unsubscribe from this list.

 

Email Marketing Powered by Mailchimp